Screen, Initiate, Protect (SIP) Campaign
A campaign that encourages regular screening for patients at risk of CKD and initiation of guideline-directed therapy such as Empagliflozin (Jardiance) to protect their kidneys early
Month 3 : Cardio-RENAL-Metabolic
Screen
CKD elevates the risk of CVD mortality when uACR>30 and/or eGFR<60
Initiate
SGLT2i is recommended as 1st line therapy in CKD according to 2024 KDIGO Guidelines
Protect
Empagliflozin (Jardiance) reduced the risk of kidney disease progression or CV death by 28% across the spectrum of uACR & eGFR
Prof. Green – How important is kidney function and albuminuria screening in people with Type 2 diabetes, and why?
Prof. Green
Prof. Jarvis – Tips on how to screen, initiate and communicate the protection of SGLT2i in T2D patients.
Prof. Jarvis
Month 2 : CKD at risk (T2D, HTN)
Month 1 : CKD
Why should medications with organ protection be initiated early for people with diabetes?
Prof Jennifer Green
